Exosect Ltd. announced it has signed its first commercial agreement with a leading agrochemical company. The formulation, uses Exosect’s proprietary formulation platform Entostat, to deliver a combination of two chemistries at significantly reduced rates, and has created a novel, proprietary insecticidal formulation for its partner.
Exosect CEO, Andrew MacNaughton comments, “I am absolutely delighted to be able to announce our first formulation out-licensing deal. Our partners are looking for new and innovative formulations which enable them to differentiate their portfolios and provide them with new intellectual property. This deal clearly validates the benefits that our Lean Formulation Technology platform can provide.”
Entostat is a proprietary micro-powder, based on natural and synthetic waxes and has electrostatic properties. It is a formulation delivery platform for a wide range of biological and synthetic active ingredients. The constituents of Entostat are listed on FIFRA’s 25(b) list of inert ingredients that can be used in pesticide products that are exempt from regulation. The electrostatic properties of Entostat enable adhesion of active ingredient to a range of surfaces including grains, seeds and pellets, insects, foliage and building structures.
The platform can assist with a range of formulation challenges such as increasing biological loading and improving the shelf life of biological material as well as reducing the concentration of synthetic active ingredients.
Exosect licenses its intellectual property to enable others to develop a differentiated product portfolio.
